IMDX
NASDAQInsight Molecular Diagnostics Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
Price$4.45-0.08 (-1.88%)
03:30 PM07:45 PM
News · 26 weeks41-17%
2026-03-012026-08-23
Mix2090d
- Other8(40%)
- Insider6(30%)
- SEC Filings4(20%)
- Earnings2(10%)
Latest news
25 items- PRInsight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection TestingNASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo, MD (Loyola University Medical Center), who will join Nick Ioannou, MD, MHA (iMDx VP Medical Affairs) and Josh Riggs (iMDx CEO), to discuss the Company's GraftAssure platform, which leverages digital PCR technology to deliver reliable dd-cfDNA results for transplanted organ health monitoring. To register, click here. The event will provide an overview of GraftAssure, currently under review by the FDA to be commercialized in kitted form for lab
- SECSEC Form 10-Q filed by Insight Molecular Diagnostics Inc.10-Q - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- SECInsight Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- PRIMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDxDiscussions with FDA advance toward expected marketing authorization for GraftAssureDxFDA completes current portion of substantive review in a timely mannerFavorable Medicare reimbursement policy issued in July significantly increases GraftAssureDx surveillance testing opportunityStrong head-to-head data drive kitted customer interest NASHVILLE, Tenn., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (NASDAQ:IMDX), today published the following letter to shareholders in conjunction with its first quarter results: Fellow shareholders, We continue to be encouraged by progress toward our most important priority, which is to attain regulatory authorization of Graf
- PRiMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 ConferenceNASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDx Q2 2026 Earnings Webinar. An archived replay will be available after the call concludes on iMDx’s website within the Investors/Events & Presentations section. Attendance at 11th Annual Needham Virtual MedTech &
- SECSEC Form S-8 filed by Insight Molecular Diagnostics Inc.S-8 - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- PRiMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group PublicationStudy published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejectionSerial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisionsNew study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trialsiMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) ("iMDx") today highlighted the publication of a new study in The Lancet Regio
- PRFavorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay PortfolioIndustry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testingSupports iMDx's commercial strategy in transplant monitoringFinal policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratoriesFinal policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care. The co
- INSIDERDirector Silverman Lou covered exercise/tax liability with 7,700 shares, decreasing direct ownership by 12% to 55,807 units (SEC Form 4) (withholding tax)4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- INSIDERDirector Last Andrew J. covered exercise/tax liability with 7,700 shares, decreasing direct ownership by 12% to 58,752 units (SEC Form 4) to satisfy withholding obligation4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- INSIDERDirector Arno Andrew covered exercise/tax liability with 12,100 shares, decreasing direct ownership by 7% to 156,785 units (SEC Form 4) to cover withholding tax4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- PRIMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research PaperKey member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58Recent studies advanced science of molecular diagnostic testing for transplanted organ rejection, published in Clinical Chemistry, Transplant International, American Journal of Transplantation and Nephrology Dialysis Transplantation, among others NASHVILLE, Tenn., June 29, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that its Chief Science Officer, Prof. Dr. Ekkehard Schuetz. M.D., Ph.D., has published his 200th scientific article. Dr. Schuetz and Dr. Julia Beck are credited a
- PRiMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation- NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), and the American Society of Transplant Surgeons (ASTS) today announced the selection of Kenneth Andreoni, MD, Surgical Director of Kidney Transplantation at Thomas Jefferson University, and Kenneth Chavin, MD, MBA, PhD, FACS, of Temple Health, as the recipients of the ASTS-iMDx Research Grant for Understanding the Health Economics of In-House versus Send-Out of donor-derived cell-free DNA (dd-cfDNA) testing. The pursuit of this research is timely as the transpla
- SECInsight Molecular Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- PRFavorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical ChemistryPeer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitorGraftAssure's industry-leading reference change value (time-point to time-point change) supports transplanted organ health screening and rejection recurrence monitoring NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX) ("iMDx") today announced the online publication of a favorable article in Clinical Chemistry, the premier, peer-reviewed scientific publication of the Association for Diagnostics & Laboratory Medicine. The article highlights the concordant performance between iMDx's digital-PCR-based flagship
- INSIDERDirector Silverman Lou was granted 26,943 shares, increasing direct ownership by 74% to 63,507 units (SEC Form 4)4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- INSIDERDirector Last Andrew J. was granted 26,943 shares, increasing direct ownership by 68% to 66,452 units (SEC Form 4)4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- INSIDERDirector Arno Andrew was granted 32,331 shares, increasing direct ownership by 24% to 168,885 units (SEC Form 4)4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)
- PRIMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of TransplantationAmerican Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA aloneGraftAssure™ assay doubles reliability of positive results in screening cohortIn for-cause testing of kidney transplant patients, the positive predictive value using the CM-Score increased to greater than 80% NASHVILLE, Tenn., June 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced an online published article in the American Journal of Transplantation asserting statistical superiority of the company's flagship GraftAssure transplant rejection monitoring assay. IMDx's newly develope
- PRiMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant CongressMultiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specificallyMajor transplantation conference in Boston will create additional awareness about GraftAssure technology and its differentiation and potential applicationsiMDx to also announce sponsorship of a grant for researchers to evaluate economics of in-house, transplanted-organ-rejection testing NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced it will be highlighting its GraftAssure™ technology at the upcoming American Transplant Congress, to be held in Boston fro
- SECSEC Form 10-Q filed by Insight Molecular Diagnostics Inc.10-Q - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- SECInsight Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- SECAmendment: Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events8-K/A - Insight Molecular Diagnostics Inc. (0001642380) (Filer)
- PRIMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure CommercializationProgressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagementNortheast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC studyBooked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming daysAnticipate significant U.S. orders to follow FDA marketing authorizationEncouraging dialogue with FDA supports expected authorization later in 2026 NASHVILLE, Tenn., May 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (NASDAQ:IMDX), today published the following letter to shareholders in conjunction with its
- PRiMDx to Release First Quarter 2026 Results on May 13, 2026NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market closes on Wednesday, May 13, 2026, then host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q1 2026 Earnings Webinar. An archived replay will be available after the call concludes on iMDX's website within the Investors/Events & Presentations section here. About Insight Molecular Diagnostics Inc.Insight Molec
IMDX FAQ
4 questionsWhere does IMDX stock trade?
Insight Molecular Diagnostics Inc. (IMDX) is listed on NASDAQ.What sector and industry is IMDX in?
Insight Molecular Diagnostics Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What companies are similar to IMDX?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), ORKA (Oruka Therapeutics Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.). Compare IMDX side-by-side with any of them on Quantisnow.How can I track IMDX on Quantisnow?
Quantisnow aggregates Insight Molecular Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMDX to receive live email and push alerts on every new disclosure.